<DOC>
	<DOCNO>NCT02225977</DOCNO>
	<brief_summary>In study wish test hypothesis continuous Gilenya treatment alters immune homeostasis favor anti-inflammatory type II monocyte macrophage ( M2 ) phenotype circulation patient relapsing-remitting Multiple Sclerosis ( MS ) . In study determine change ratio M2 ( type II , alternatively activate ) versus M1 ( type I , classically activate ) monocytes macrophage cohort patient receive continuous Gilenya treatment 0 , 1 , 3 , 6 12 month . We also assess change cell surface expression M1 marker CCR7 M2 marker CD206 CD301 monocytes macrophage use FACS analysis whole blood , assess tyrosine phosphorylation signal transducer activator transcription STAT-1 ( pTyr-STAT1 ) , critical activation M1 myeloid cell . We assess correlate change M1 M2 cytokine expression assess possible mechanisms action Gilenya myeloid lineage cell .</brief_summary>
	<brief_title>Assessing Induction Type II ( M2 ) Monocytes/Macrophages Patients Receiving Gilenya .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients must qualify receive treatment Gilenya , accord University Southern California , Department Neurology , MS Group , Gilenya Prescribing Process . Clinically definite Multiple Sclerosis define revise McDonald criterion ( Polman et al. , 2005 , Polman et al. , 2010 ) relapsingremitting form Expanded Disability Status Scale ( EDSS ) score 0 5.5 . Ability understand sign studyspecific institutional review boardapproved informed consent form . Willing donate ~50mls blood immunological test five occasion . Patient qualify receive treatment Gilenya , accord USC , Department Neurology , MS Group , Gilenya Prescribing Process . Inability understand nature study . Treatment follow within 30 day commence treatment Gilenya : Avonex , Betaseron , Rebif , Copaxone , Natalizumab , Rituximab , Mitoxantrone , Cyclophosphamide , Cyclosporine , Azathioprine , Methotrexate immunomodulatory , immunosuppressant immune homeostasis alter drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>